These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16981002)

  • 1. Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter.
    Clark R; Kerr ID; Callaghan R
    Br J Pharmacol; 2006 Nov; 149(5):506-15. PubMed ID: 16981002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.
    Ozvegy C; Váradi A; Sarkadi B
    J Biol Chem; 2002 Dec; 277(50):47980-90. PubMed ID: 12374800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is ATP binding responsible for initiating drug translocation by the multidrug transporter ABCG2?
    McDevitt CA; Crowley E; Hobbs G; Starr KJ; Kerr ID; Callaghan R
    FEBS J; 2008 Sep; 275(17):4354-62. PubMed ID: 18657189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
    Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
    Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.
    Tamura A; Watanabe M; Saito H; Nakagawa H; Kamachi T; Okura I; Ishikawa T
    Mol Pharmacol; 2006 Jul; 70(1):287-96. PubMed ID: 16608919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
    Ozvegy-Laczka C; Köblös G; Sarkadi B; Váradi A
    Biochim Biophys Acta; 2005 Feb; 1668(1):53-63. PubMed ID: 15670731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
    Henriksen U; Gether U; Litman T
    J Cell Sci; 2005 Apr; 118(Pt 7):1417-26. PubMed ID: 15769853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A template model for studying anticancer drug efflux transporter inhibitors in vitro.
    Sostelly A; Payen L; Guitton J; Di Pietro A; Falson P; Honorat M; Valdameri G; Geze A; Boumendjel A; Freyer G; Tod M
    Fundam Clin Pharmacol; 2013 Oct; 27(5):544-56. PubMed ID: 22882086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
    Chearwae W; Shukla S; Limtrakul P; Ambudkar SV
    Mol Cancer Ther; 2006 Aug; 5(8):1995-2006. PubMed ID: 16928820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2.
    Henriksen U; Fog JU; Litman T; Gether U
    J Biol Chem; 2005 Nov; 280(44):36926-34. PubMed ID: 16107343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites.
    Telbisz Á; Hegedüs C; Váradi A; Sarkadi B; Özvegy-Laczka C
    Drug Metab Dispos; 2014 Apr; 42(4):575-85. PubMed ID: 24384916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2.
    Pál A; Méhn D; Molnár E; Gedey S; Mészáros P; Nagy T; Glavinas H; Janáky T; von Richter O; Báthori G; Szente L; Krajcsi P
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1085-94. PubMed ID: 17347325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A.
    Ejendal KF; Hrycyna CA
    Mol Pharmacol; 2005 Mar; 67(3):902-11. PubMed ID: 15598974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.
    Kuang YH; Patel JP; Sodani K; Wu CP; Liao LQ; Patel A; Tiwari AK; Dai CL; Chen X; Fu LW; Ambudkar SV; Korlipara VL; Chen ZS
    Biochem Pharmacol; 2012 Sep; 84(6):766-74. PubMed ID: 22750060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells.
    Shukla S; Schwartz C; Kapoor K; Kouanda A; Ambudkar SV
    Drug Metab Dispos; 2012 Feb; 40(2):304-12. PubMed ID: 22041108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.
    Takara K; Yamamoto K; Matsubara M; Minegaki T; Takahashi M; Yokoyama T; Okumura K
    PLoS One; 2012; 7(2):e30697. PubMed ID: 22355323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.
    Zhang F; Throm SL; Murley LL; Miller LA; Steven Zatechka D; Kiplin Guy R; Kennedy R; Stewart CF
    Biochem Pharmacol; 2011 Jul; 82(1):24-34. PubMed ID: 21459080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.
    To KK; Tomlinson B
    Br J Pharmacol; 2013 Nov; 170(5):1137-51. PubMed ID: 24032744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.